Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.

Learn More

From Promise to Therapy

Seattle Genetics is conducting clinical trials in these and other therapeutic areas:

  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma
  • Urothelial cancer
  • Breast cancer

View all clinical trials

Join The Seattle Genetics Team

We are a group of passionate innovators dedicated to positively impacting the lives of those living with cancer, and we're always looking to add to our team.

Learn More

Recent News

Seattle Genetics Announces Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer More

Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer More

Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer More

View All News

Seattle Genetics At A Glance

Year founded 1998

Global Headquarters Bothell, WA

Nasdaq SGEN

Number of Employees 1,000+

Clinical & preclinical pipeline programs 12+

ADCs in clinical trials using our technology 20+